Recent advances in breast cancer research impacting clinical diagnostic practice

During the last decade, the genomics revolution has driven critical advances in molecular oncology and pathology, and a deeper appreciation of heterogeneity that is beginning to reshape our thinking around diagnostic classification. Recent developments have seen existing classification systems modif...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pathology 2019-04, Vol.247 (5), p.552-562
Main Authors: McCart Reed, Amy E, Kalita‐De Croft, Priyakshi, Kutasovic, Jamie R, Saunus, Jodi M, Lakhani, Sunil R
Format: Article
Language:English
Subjects:
Breast cancer
Breast Cancer Index
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer immunotherapy
Cancer research
Classification systems
Clinical trials
EndoPredict (EPclin)
Female
Genes, BRCA1 - physiology
Genes, BRCA2 - physiology
Genes, Neoplasm - genetics
genomic signatures
Genomics
Heterogeneity
Humans
Lymphocytes, Tumor-Infiltrating - physiology
MammaPrint
MapQuantDx
Molecular Targeted Therapy - methods
Oncology
OncotypeDX
pathology
PD‐1
PD‐L1
Prognosis
prognostic signatures
Prosigna
triple negative
Tumors
tumour‐infiltrating lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last decade, the genomics revolution has driven critical advances in molecular oncology and pathology, and a deeper appreciation of heterogeneity that is beginning to reshape our thinking around diagnostic classification. Recent developments have seen existing classification systems modified and improved where possible, gene‐based diagnostics implemented and tumour–immune interactions modulated. We present a detailed discussion of this progress, including advances in the understanding of breast tumour classification, e.g. mixed ductal–lobular tumours and the spectrum of triple‐negative breast cancer. The latest information on clinical trials and the implementation of gene‐based diagnostics, including MammaPrint and Oncotype Dx and others, is synthesised, and emerging targeted therapies, as well as the burgeoning immuno‐oncology field, and their relevance in breast cancer, are discussed. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
ISSN:0022-3417
1096-9896
DOI:10.1002/path.5199